ADA: Victoza's 'Broad' CV Benefit Leads The Way For Semaglutide

Full cardiovascular (CV) outcomes data for Novo Nordisk AS's leading diabetes therapy, Victoza (liraglutide), show positive effects across a wide range of CV endpoints – placing the company in a strong position with the first GLP-1 product and second ever diabetes therapy to show a benefit on CV mortality.